Loading
Endoplasmic Reticulum Stress and Disease / Cancer, Hypoxia, and Metabolism · Journal article
Cell Death Discovery · August 10, 2026
Raises a question worth testing. It does not answer one.
This is a discovery-stage study using artificial intelligence to design protein minibinders that inhibit a redox regulatory axis (ERO1A–PDIA1) implicated in triple-negative breast cancer. Three candidate minibinders bound PDIA1 and inhibited its enzymatic function in vitro, and liposome delivery of one minibinder reduced TNBC cell viability in culture, establishing proof-of-concept but providing no evidence of efficacy in living systems.
In vitro biochemical and cell-based mechanistic study with computational protein design. TNBC cells (line and details not specified) and recombinant ERO1A and PDIA1 proteins for biochemical assays.. Intervention: AI-designed protein minibinders targeting PDIA1 b′ domain, with liposome-mediated intracellular delivery of mb7..
Eight top-scoring, non-redundant minibinder candidates were selected from one hundred AI-designed candidates targeting PDIA1 b′ domain Three minibinders demonstrated direct binding to PDIA1 and inhibited ERO1A–PDIA1 electron transfer relay in vitro Three minibinders inhibited the intrinsic reductase activity of PDIA1 in biochemical assays
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is at the target identification and hit discovery stage. It is too early to guide clinical practice; further development through structural optimization, in vivo efficacy studies, and eventual clinical translation would be needed to evaluate therapeutic potential.
Early-stage mechanistic work using AI-designed protein tools to target a redox pathway in TNBC, demonstrating proof-of-concept in vitro and in cell culture without efficacy data in living organisms or patients.
As stated by the source record.
Quoted from the source exactly as published.
This work is at the target identification and hit discovery stage. It is too early to guide clinical practice; further development through structural optimization, in vivo efficacy studies, and eventual clinical translation would be needed to evaluate therapeutic potential.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Endoplasmic reticulum oxidoreductin 1 alpha (ERO1A), together with its partner protein disulfide isomerase A1 (PDIA1), promotes oxidative protein folding within the endoplasmic reticulum (ER), thereby supporting ER redox homeostasis, proteostasis, and cancer progression. Importantly, ERO1A enhances the aggressiveness and therapy resistance of triple-negative breast cancer (TNBC), while PDIA1 is also upregulated and positively correlates with ERO1A expression in TNBC. These observations suggest that targeting the ERO1A–PDIA1 interaction may simultaneously impair the activity of both proteins, thereby providing a dual-hit anti-cancer strategy. Guided by AI-based structural modeling of the ERO1A–PDIA1 interface, we used the BindCraft pipeline to design and rank one hundred de novo protein minibinders targeting the b′ domain of PDIA1, from which eight top-scoring, non-redundant candidates were selected for experimental characterization. In vitro biochemical assays using recombinant proteins demonstrated direct binding of three minibinders (mb) to PDIA1 and inhibition of both the ERO1A–PDIA1 electron transfer relay and the intrinsic reductase activity of PDIA1. Furthermore, liposome-mediated intracellular delivery of mb7 impaired TNBC cell viability, providing proof-of-concept evidence that the minibinder can restrain tumor cell survival. Overall, our work provides a rationale for the development of highly specific and stable protein-based modulators of the ERO1A–PDIA1 interaction, which, by simultaneously inhibiting the activities of both ERO1A and PDIA1, may represent an effective strategy to restrain TNBC progression and counteract therapy resistance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.